

Vascular endothelial growth factor A inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/V7141DFE7E3EN.html>

Date: January 2022

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: V7141DFE7E3EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Understanding

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Overview

The VEGF (vascular endothelial growth factor) pathway has emerged as an important target for cancer therapy, with VEGF signaling pathway (VSP) inhibitors having been approved for several different malignancies. The human VEGF family consists of 5 related glycoproteins: VEGFA, VEGFB, VEGFC, VEGFD, and PlGF (placental growth factor). These are secreted to form homodimers, which interact with a family of 3 receptor tyrosine kinases: VEGFR1 (VEGF receptor 1), VEGFR2, and VEGFR3. VEGFA and VEGFB bind to VEGFR1, VEGFA binds to VEGFR2, and VEGFC and

VEGFD bind to both VEGFR2 and VEGFR3.

VSP inhibitors have been found to reduce NO pathway metabolites and NO-dependent processes. Inhibition of VEGF pathway is a strategy being widely pursued to provide new therapeutics for the treatment of VEGF related disorders.

Novel antiangiogenic cancer therapies, particularly agents that block vascular endothelial growth factor (VEGF) signalling, have improved outcomes in patients with cancers and are now used as first-line therapies for some tumours. However, with VEGF inhibitors (VEGFIs) are new complications, particularly hypertension. VEGFI-induced hypertension is a dose-dependent phenomenon due to on-target effects rather than off-target effects.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor R&D. The therapies under development are focused on novel approaches for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor.

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Emerging Drugs Chapters

This segment of the Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Emerging Drugs

SOK583A1: Sandoz

Aflibercept binds and inhibits ocular VEGF-A and prevents abnormal growth of blood vessels in the choroid, impacting visual function. It improves visual acuity in patients with neovascular retinal diseases like nAMD, DME, and RVO. SOK583A1 is a biosimilar of Aflibercept (Eylea).

It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Sandoz, a division of Novartis.

VK-2809: Viking Therapeutics

VK2809 is an orally available small molecule agonist of the thyroid hormone receptor that possesses selectivity for liver tissue, as well as the beta receptor subtype, and has demonstrated promising therapeutic potential in a range of lipid disorders, including NASH.

It is currently in Phase II stage of development and is being developed by Viking Therapeutics.

Further product details are provided in the report.....

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor

There are approx. 40+ key companies which are developing the Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor. The companies which have their Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Sandoz.

Phases

DelveInsight's report covers around 40+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs.

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Report Insights

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs?

How many Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Sandoz

Sam Chun Dang Pharm

Samsung Bioepis

Luye Pharma

Shanghai Henlius Biotech

Generium Pharmaceuticals

Bioeq GmbH

Roche

Chong Kun Dang Pharmaceutical

Outlook Therapeutics

Qilu Pharmaceuticals

AngioLab

Sinocelltech

Alteogen

Adverum Biotechnologies

Boehringer Ingelheim

EyevenSys

Oxford BioMedica

Key Products

SOK583A1

SCD411

SB15

LY09004

HLX04-O

GNR-067

Faricimab

FYB203

CKD-701

ONS-5010

BCD 300

ALS-L1023

SCT510A

ALT-L9

ADVM-022

BI 836880

EYS609

OXB-203

Contents

Introduction

Executive Summary

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor : Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor companies' collaborations, Licensing, Acquisition -Deal Value Trends

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

SOK583A1: Sandoz

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

ALS-L1023: AngioLab

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

ALT-L9: Alteogen

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

Comparative Analysis

EYS609: Eyevensys

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Key Companies

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Key Products

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Unmet Needs

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Market Drivers and Barriers

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Future Perspectives and

Conclusion

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Analyst Views

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Vascular endothelial growth factor A inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Vascular endothelial growth factor A inhibitors

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Vascular endothelial growth factor A inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/V7141DFE7E3EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V7141DFE7E3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970